Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Long-term prognostic factors for PRRT in neuroendocrine tumors.
Trautwein NF, Schwenck J, Jacoby J, Reischl G, Fiz F, Zender L, Dittmann H, Hinterleitner M, la Fougère C. Trautwein NF, et al. Front Med (Lausanne). 2023 Jun 9;10:1169970. doi: 10.3389/fmed.2023.1169970. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37359009 Free PMC article.
First-in-Humans PET/MRI of In Vivo GD2 Expression in Osteosarcoma.
Trautwein NF, Reischl G, Seitz C, Dittmann H, Seith F, Scheuermann S, Feuchtinger T, Dombrowski F, Handgretinger R, Fuchs J, Pichler B, Fougère C, Schwenck J. Trautwein NF, et al. J Nucl Med. 2023 Feb;64(2):337-338. doi: 10.2967/jnumed.122.264626. Epub 2022 Sep 15. J Nucl Med. 2023. PMID: 36109181 Free PMC article. No abstract available.
Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.
Hinterleitner M, Pfeiffer R, Trautwein NF, Sipos B, Singer S, Nadalin S, Königsrainer A, Lauer UM, la Fougère C, Zender L, Hinterleitner C. Hinterleitner M, et al. Among authors: trautwein nf. Front Endocrinol (Lausanne). 2024 Jan 8;14:1285529. doi: 10.3389/fendo.2023.1285529. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38260136 Free PMC article.
Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.
Trautwein NF, Hinterleitner C, Kiefer LS, Singer S, Mattern S, Schwenck J, Reischl G, Sipos B, Lauer UM, Dittmann H, Zender L, la Fougère C, Hinterleitner M. Trautwein NF, et al. Clin Nucl Med. 2024 Mar 1;49(3):207-214. doi: 10.1097/RLU.0000000000005006. Epub 2024 Jan 23. Clin Nucl Med. 2024. PMID: 38271237